Endomedix, Inc. Employee Directory

Medical Equipment ManufacturingNew Jersey, United States2-10 Employees

Endomedix is a development stage, Medical Device venture, a C corp. The Company has developed a tunable polysaccharide platform that can produce a family of new biomaterials. The first spinoff of this platform is PlexiClot™ Absorbable Hemostat to control bleeding in brain & spinal surgeries, a $1.9B market. PlexiClot introduces the first fundamental innovation in bleeding control in these procedures since the current standard of care was introduced in 1945. The innovation is based on new mechanisms of action that will likely obsolete the current methods of relying on the biochemical action of thrombin and manual pressure to produce coagulation. PlexiClot will eliminate one cause of reoperations caused by current devices as documented in dozens of clinical publications. In addition to reducing the incidence of complications, PlexiClot is poised to save hospitals hundreds of millions of dollars in unreimbursed costs due to reoperation, lengthy hospital stays and early readmission to hospitals. PlexiClot’s performance has been confirmed in 3 large animal trials, and Endomedix is currently planning to scale up production. 

PlexiClot’s composition of matter, method of manufacture and mechanisms of action are protected by 8 issued patents, the most important of which expire in 2038.

The Endomedix team is led by Richard Russo, a medical device vet with experience in prior start-ups with exits, and he is the lead cash investor. He has a history of success with new products, clinical & regulatory, and international. R&D is led by Piyush Modak, who leverages a small internal team through a constellation of renown subject matter experts. 18 neurosurgeons & physicians are investors. PlexiClot will be the 1st device approved by FDA specifically for brain surgery. This sector is marked by a high level of M&A activity, much of which occurs prior to final FDA approval. The program has drawn interest & support from surgeons and physicians, 18 of whom are investors.

Sign up for free to view info

Company overview Email format